

BMS-641988

## Chemical Properties


CAS No. : 1093276-09-5

Formula: C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S

Molecular Weight: 471.45

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	BMS-641988 is a novel nonsteroidal androgen receptor antagonist for the treatment of prostate cancer.
Targets(IC50)	Androgen Receptor
In vivo	Sixty-one men with CRPC were treated with daily BMS-641988 (5 to 150 mg). Seventeen of 23 evaluable patients (74%) exhibited stable disease on imaging (median 15 weeks; range 8-32), and 10 of 61 patients (16%) achieved a $\geq 30\%$ decline in levels of prostate-specific antigen (PSA).[1]

## Solubility Information

Solubility	DMSO: 50 mg/mL (106.06 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: $< 5$ mg/mL (10.61 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.61 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.1211 mL	10.6056 mL	21.2112 mL
5 mM	0.4242 mL	2.1211 mL	4.2422 mL
10 mM	0.2121 mL	1.0606 mL	2.1211 mL
50 mM	0.0424 mL	0.2121 mL	0.4242 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Rathkopf D, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011;17(4):880-887.

Attar RM, et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res. 2009;69(16):6522-6530.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481